国内硼替佐米联合化疗方案治疗多发性骨髓瘤的Meta分析第4O卷第5期第618页2011年1O月华中科技大学(医学版)Vo1.40No.5P.618AetaMedUnivSciTechnolHuazhongOct.2011国内硼替佐米联合化疗方案治疗多发性骨髓瘤的Meta分析吕静,吕勤.,朱殿秋,吴秋枫,邱宇珍,杨玉梅武汉科技大学附属天佑医院急诊科,武汉430064华中科技大学同济医学院公共卫生学院流行病与卫生统计学系,武汉430030.武汉市二七街社区卫生服务中心,武汉430017摘要:目的评价国内硼替佐米治疗多发性骨髓瘤的疗效与安全性.方法计算机检索中国知识资源总库CNKI,万方数据库,中国科技期刊数据库(重庆维普),检索年限从硼替佐米开始在中国临床应用至今(2005～2010年).手工检索所有纳人文献的相关参考文献,筛选硼替佐米治疗多发性骨髓瘤的随机对照试验,进行资料提取后,采用STATA11软件进行Meta分析.结果共纳入7个随机对照临床试验(RCT),包括301例患者.Meta分析结果显示,硼替佐米联合化疗方案与单用MP(马法兰,泼尼松),M2(卡氮芥,环磷酰胺,长春新碱)和VAD(马法兰或长春新碱,阿霉素,地塞米松)方案比较,其治疗缓解率[RR:1.40,95CI(1.08,1.81)]和总有效率LRR一1.29,95%CI(1.o3,1.61)]差异均有统计学意义.结论目前国内的有限证据表明,与用MPM2或VAD方案相比,硼替佐---本文来源于网络，仅供参考，勿照抄，如有侵权请联系删除---米联合化疗方案能增加多发性骨髓瘤治疗的总有效率和缓解率,但由于纳入研究样本量小且质量较低,上述结论尚需要高质量,大样本的随机双盲对照试验加以证实.关键词:硼替佐米;多发性骨髓瘤;化疗;Meta分析:R733.3DOI:10.3870/j.issn.1672—0741.2Ol1.05.030Meta—analysisofBortezomibCombinedwithOtherDrugsforChemotherapyintheTreatmentofMultipleMyelomaIv激ng～,LvQin.,ZhuDianqiuetalDepartmentoJEmergencyMedicine,TianyouHospital,AffiliatedtoWuhanUniversityofScienceandTechnology,Wuhan430064,China.DepartmentofEpidemiologyandHealthStatistics,Tong激MedicalCollege,HuazhongUniversityofScienceandTechnology,Wuhan430030,ChinaCommunityHealthServiceCenter0fStreet27,Wuhan430017,ChinaAbstractOhjectiveToevaluatetheefficacyandsafetyofbortezomibcombinedwithotherdrugsforchemotherapyinthetreatmentofmultiplemyeloma.MethodsTheCNKI,WangfangData,andChineseScienceandTechnologyPeriodicalDatabase(ChongqingVIP)weresearchedfor1iterature.RetrievalperiodwasstartedfrombortezomibforclinicalapplicationsinChinasince2005tO2010.Manua1retrieva1ofallrelevantliteraturereferencesincludedscreeningbortezomibtreatmentofmultiplemy—elomainrandomizedcontrolledtrials(RCT).STATA1lsoftwarewasusedforMeta-analysisafterextractingtheusefulda—ta.ResultsAtotalofsevenRCTwerecollected.including301cases.Meta—analysisshowedthatincomparisonofbortezomibcombinedwithotherdrugsforchemotherapywithsingleMP,M2,orVADregimen,therewasstatisticallysignificantdifference---本文来源于网络，仅供参考，勿照抄，如有侵权请联系删除---intheresponserate~RR一1.4o,95CI(1.o8,1.81)3andtota1effectiverate[RR一1.29,95%CI(1.O3,1.61)].ConclusionAccordingtotheIimiteddomesticevidence,comparedtosingleMP,M2,orVADprogram.bortezomibcombinedwithotherdrugsforchemotherapyinthetreatmentofmultiplemyelomaincreasedtheoverallefficiencyandresponserate.However,highquality,largesample.randomized,doubleblindcontrolledtrialsarerequired.Keywordsbortezomib;multipiemyeloma;chemotherapy;Metaanalysis多发性骨髓瘤(multiplemyeloma,MM)是以浆细胞异常增殖为特点的血液系统恶性肿瘤.研究表明,目前的传统化疗方案,使用马法兰,泼尼松(MP吕静,女,1974年生,主治医师,硕士研究生,E—mail:408911348@qq?tom方案),卡氮芥,环磷酰胺,长春新碱(M2方案)和马法兰或长春新碱,阿霉素,地塞米松(VAD方案)等标准方案治疗有效率为7o%,但完全缓解(CR)率不高,约3～l...